REPL Key Statistics, Chart & Performance
The current stock price of REPL is 7.675 USD. In the past month the price decreased by -21.02%. In the past year, price decreased by -20.71%.
REPL Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to REPL. When comparing the yearly performance of all stocks, REPL is one of the better performing stocks in the market, outperforming 87.29% of all stocks.
REPL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to REPL. The financial health of REPL is average, but there are quite some concerns on its profitability.
REPL Financial Highlights
Over the last trailing twelve months REPL reported a non-GAAP Earnings per Share(EPS) of -3.46. The EPS decreased by -13.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.58% | ||
| ROE | -117.69% | ||
| Debt/Equity | 0.26 |
REPL Forecast & Estimates
14 analysts have analysed REPL and the average price target is 12.82 USD. This implies a price increase of 67.07% is expected in the next year compared to the current price of 7.675.
For the next year, analysts expect an EPS growth of -19.28% and a revenue growth -100% for REPL
REPL Ownership
REPL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.53 | 392.93B | ||
| AMGN | AMGEN INC | 15.04 | 177.13B | ||
| GILD | GILEAD SCIENCES INC | 15.14 | 153.88B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.9 | 114.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.76 | 79.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 718.9 | 48.44B | ||
| INSM | INSMED INC | N/A | 34.80B | ||
| NTRA | NATERA INC | N/A | 33.02B | ||
| BIIB | BIOGEN INC | 10.11 | 24.82B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.39B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18 | 20.46B | ||
| INCY | INCYTE CORP | 16.51 | 20.81B |
Related stock screener links
About REPL
Company Profile
Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Company Info
REPLIMUNE GROUP INC
500 Unicorn Park Dr
Woburn MASSACHUSETTS 01801 US
CEO: Philip Astley-Sparke
Employees: 479
Phone: 17812229600
REPLIMUNE GROUP INC / REPL FAQ
What does REPL do?
Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
What is the stock price of REPLIMUNE GROUP INC today?
The current stock price of REPL is 7.675 USD. The price decreased by -4.54% in the last trading session.
Does REPL stock pay dividends?
REPL does not pay a dividend.
How is the ChartMill rating for REPLIMUNE GROUP INC?
REPL has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is REPLIMUNE GROUP INC (REPL) stock traded?
REPL stock is listed on the Nasdaq exchange.
Can you provide the market cap for REPLIMUNE GROUP INC?
REPLIMUNE GROUP INC (REPL) has a market capitalization of 602.03M USD. This makes REPL a Small Cap stock.
Can you provide the upcoming earnings date for REPLIMUNE GROUP INC?
REPLIMUNE GROUP INC (REPL) will report earnings on 2026-02-10.